Last October Smithsonian Folkways released “The Brothers Nazaroff: The Happy Prince,” a boisterous, high-energy tribute to cult Yiddish troubadour Nathan “Prince” Nazaroff, who recorded the […]

The post Animated Music Video: “Ich A Mazeldicker Yid” by The Brothers Nazaroff appeared first on Smithsonian Insider.

Judy Garland’s iconic ruby slippers from “The Wizard of Oz” are one of the most popular attractions at the National Museum of American History. But […]

The post Crowdfunding campaign to restore Ruby Slippers surpasses mark appeared first on Smithsonian Insider.

The French-German border is littered with as many as 500 underground sites used during World War I. Researcher Jeff Gusky explores them and finds a […]

The post Quarry carvings by American WWI soldiers appeared first on Smithsonian Insider.

White-faced capuchin monkeys in Panama’s Coiba National Park habitually use hammer-and-anvil stones to break hermit crab shells, snail shells, coconuts and other food items, according […]

The post Scientists observe stone tool use by Cebus monkeys appeared first on Smithsonian Insider.

Follow botanist Candy Feller of the Smithsonian Environmental Research Center as she conducts field work on mangrove ecosystems at Carrie Bow Cay, a Smithsonian field research station in the Caribbean.

The post Mangroves research by Candy Feller, Smithsonian Environmental Research Center botanist appeared first on Smithsonian Insider.

How do you diagnose a sick stream? Count its insects, according to Smithsonian biologist Don Weller.

The post Streams damaged by too many hard surfaces in urban areas appeared first on Smithsonian Insider.

When Gary Graves cranks up his boom box and drives remote back roads through pine plantations in Texas, Louisiana and other southern states, a few […]

The post Rare American warbler surprises scientists by adapting, thriving in a new ecosystem appeared first on Smithsonian Insider.

In the dark recesses of an underground fungus garden, a Panamanian leaf-cutting ant plucks a tuft of mycelia, the wispy part of the basidiomycete fungus […]

The post Mystery solved? Ants Protect Young From Infection By Cocooning Them in Fungus appeared first on Smithsonian Insider.

During the course of a year, a western gorilla in the Lossi Forest of Northern Congo stuffs its face with a profusion of fruit, including figs, […]

The post Gorillas Aren’t Tricked By a Faux Sugary Fruit Thanks to a Mutation appeared first on Smithsonian Insider.

Is it foolish to be optimistic about our environment and its future prospects? Every day, we hear dire warnings about the health of the planet […]

The post The Argument for Environmental Optimism: Opinion by Smithsonian Secretary David J. Skorton appeared first on Smithsonian Insider.

Structure-mining finds and returns the best-fit structures from structural databases given a measured pair distribution function data set. Using databases and heuristics for automation it has the potential to save experimenters a large amount of time as they explore candidate structures from the literature.

To describe multiple Bragg reflection from a thick, ideally imperfect crystal, the transport equations are reformulated in three-dimensional phase space and solved by spectral collocation in the depth coordinate. Example solutions illustrate the orientational spread of multiply reflected rays and the distortion of rocking curves, especially for finite detectors.

(The Paypers)

Georgi Dimchev
Apr 9, 2020; 133:jcs239020-jcs239020
Articles

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Good morning and welcome. There has been unprecedented interest in recent years about whether marijuana or its constituent compounds should be used as medicine. Since 1996, voters in seven states have approved the medical use of marijuana.

Focused attention by world leaders is needed to address the substantial challenges posed by disposal of spent nuclear fuel from reactors and high-level radioactive waste from processing such fuel for military or energy purposes.

Good morning. I am Richard Bonnie, chair of the Committee on Developing a Strategy to Reduce and Prevent Underage Drinking.

Welcome to the public release of the latest Institute of Medicine report on the quality of health care in America.

Good morning. I am Dr. Alice Gast and I am here today with Dr. David Relman as the chair and vice chair of the Committee on the Review of the Scientific Approaches Used During the FBI’s Investigation of the 2001 Bacillus anthracis Mailings.

The National Academy of Sciences today announced the election of 72 new members and 18 foreign associates from 14 countries in recognition of their distinguished and continuing achievements in original research.

An analysis of more than 1,000 research articles concluded that few health problems are caused by or clearly associated with vaccines.

The analysis used by federal agencies to set standards for fuel economy and greenhouse gas emissions for new U.S. light-duty vehicles -- passenger cars and light trucks -- from 2017 to 2025 was thorough and of high caliber overall, says a new report from the National Research Council.

As the gap in life expectancy between the highest and lowest earners in the U.S. has widened over time, high earners have disproportionately received larger lifetime benefits from government programs such as Social Security and Medicare, says a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine.

We thank the organizers of our International Summit on Human Gene Editing for their thoughtful concluding statement and welcome their call for us to continue to lead a global discussion on issues related to human gene editing.

Despite the importance of eyesight, millions of people grapple with undiagnosed or untreated vision impairments — ranging from mild conditions to total blindness — and eye and vision health remain relatively absent from national health priority lists, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The National Academies Committee on Genetically Engineered Crops - Past Experiences and Future Prospects authored an almost 600-page landmark report, released in May 2016. It was perhaps the most comprehensive analysis of genetically engineered crops to date.

Hepatitis B and C kill more than 20,000 people every year in the United States.

Given the possible security vulnerabilities related to developments in synthetic biology – a field that uses technologies to modify or create organisms or biological components – a new report by the National Academies of Sciences, Engineering, and Medicine proposes a framework to identify and prioritize potential areas of concern associated with the field.

Producing more precise county-level estimates of crops and farmland cash rents will require integrating multiple data sources using model-based predictions that are more transparent and reproducible, says a new report from the National Academies of Sciences, Engineering, and Medicine.

We are concerned deeply by a report that staff at the Centers for Disease Control and Prevention were instructed not to use certain words in budget documents. As leaders of the National Academies of Sciences, Engineering, and Medicine, we are especially stunned that “evidence-based” and “science-based” are reportedly among the barred terms.

The highest standards of scientific integrity, transparency, and accountability are critical to maintaining public confidence in our nation’s research enterprise and in the wise use of the public investment in research.

We are pleased to announce that the National Academies of Sciences, Engineering, and Medicine are exploring ways to mobilize our expertise to counter misinformation on the web related to science, engineering, and health.

The Gulf Research Program (GRP) of the National Academies of Sciences, Engineering, and Medicine today announced 11 grant awards totaling $341,283 to assist in the recovery of Gulf Coast scientific research efforts impacted by hurricanes Harvey and Irma.

Sexual harassment in science, engineering, and medicine diminishes the integrity of the U.S. research enterprise.

The Gulf Research Program (GRP) of the National Academies of Sciences, Engineering, and Medicine today announced 11 grant awards totaling $287,565 to assist in the recovery of Gulf of Mexico region scientific research efforts impacted by hurricanes Harvey and Irma.

A new report from the National Academies of Sciences, Engineering, and Medicine identifies the most promising scientific breakthroughs that are possible to achieve in the next decade to increase the U.S. food and agriculture system’s sustainability, competitiveness, and resilience.

A new report from the National Academies of Sciences, Engineering, and Medicine outlines a research agenda for improving the commercial viability of technologies that turn greenhouse gases from the burning of fossil fuels into useful products such as fuels, construction materials, and chemicals.

In December 2015, the U.S. National Academy of Sciences and U.S. National Academy of Medicine, the Royal Society of the United Kingdom, and the Chinese Academy of Sciences hosted an international summit in Washington, D.C., to discuss scientific, ethical, and governance issues associated with human genome editing.

Following recommendations from a National Academies of Sciences, Engineering, and Medicine report released earlier this year, the National Academies’ Gulf Research Program (GRP) is developing a long-term research campaign to improve understanding and prediction of the Gulf of Mexico Loop Current System (LCS).

The Gulf Research Program of the National Academies of Sciences, Engineering, and Medicine announced today the recipients of its 2019 Early-Career Research Fellowships.